Dr. Jochen H. Lorch, M.D.
Claim this profileNorthwestern University
Studies Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
25 drugs studied
Area of expertise
1Cancer
Stage IV
PD-L1 positive
Stage III
2Squamous Cell Carcinoma
Stage IV
PD-L1 positive
Stage III
Affiliated Hospitals
Clinical Trials Jochen H. Lorch, M.D. is currently running
AIC100 CAR T Cells
for Thyroid Cancer
This trial tests a new treatment using modified immune cells to fight certain types of thyroid cancer that haven't responded to other treatments. The patient's own cells are changed in a lab to better target and kill cancer cells, then reintroduced into their body. This new method aims to improve the ability of the patient's immune system to find and destroy cancer cells.
Recruiting1 award Phase 110 criteria
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
More about Jochen H. Lorch, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Jochen H. Lorch, M.D. has experience with
- Pembrolizumab
- Cisplatin
- Nivolumab
- Carboplatin
- Platinum
- 5-fluorouracil
Breakdown of trials Jochen H. Lorch, M.D. has run
Cancer
Squamous Cell Carcinoma
Thyroid Disease
Thyroid Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jochen H. Lorch, M.D. specialize in?
Jochen H. Lorch, M.D. focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Jochen H. Lorch, M.D. currently recruiting for clinical trials?
Yes, Jochen H. Lorch, M.D. is currently recruiting for 10 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jochen H. Lorch, M.D. has studied deeply?
Yes, Jochen H. Lorch, M.D. has studied treatments such as Pembrolizumab, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Jochen H. Lorch, M.D.?
Apply for one of the trials that Jochen H. Lorch, M.D. is conducting.
What is the office address of Jochen H. Lorch, M.D.?
The office of Jochen H. Lorch, M.D. is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.